PARP Inhibitors - Are They a New Type of Cancer Treatment? New Clinical Trials Suggest "Yes"

A PARP is also known as a Poly (ADP-ribose)PARP Inhibitors are currently being trialled for use
polymerase and it repairs damage done to ourin ovarian, breast and prostate cancer and are
body, it is a useful function and basically a PARPbeing trialled targeting mutations in the BRCA1 and
enzyme regulates our body, repairing damagedBRCA2 genes. One of the reasons this drug is
DNA. Usually this is a normal function which stopssuch a promising target is that it has shown
cell death however Doctor de Bono and hissignificant anti-tumor effects and yet has caused
colleagues have done research to suggest thatno side effects (doesn't appear needed for
cancer cells may use PARP repair method to theirgeneral healthy functioning) for those that have
advantage.received the parp inhibitors. If PARP trials prove
An inhibitor cancer drug is a new type of cancerto be successful this may be one of the most
treatment which inhibits (stops) a function thatexciting cancer treatments we have seen for a
cancer uses to its advantage. One of these is thelong time.
PARP function. Currently PARP inhibitor clinical trialsCurrently one woman on the trial has shown a full
are featuring two parp drugs named BSI 201recovery from advanced PARP breast cancer,
(BiPar Sciences) and Olaparib (Astra Zeneca).whilst this is not a cure for cancer it has shown
These PARP inhibitors are in phase two trials andpromising early signs in one third of those treated
have been proclaimed to be a majorhas reduced the size of tumors.
breakthrough in cancer research.